Explorez tous les épisodes du podcast The Lancet Haematology in conversation with
| Titre | Date | Durée | |
|---|---|---|---|
| Lancet Haematology 10 year anniversary - meet the editors | 02 Oct 2024 | 00:47:21 | |
In a special 10 year anniversary podcast, Lan-Lan Smith, Yaiza del Pozo Martin, and Emma Cookson, the editorial team behind The Lancet Haematology, reflect on the last decade and give some insights into the editorial processes at The Lancet Group. Continue this conversation on social! | |||
| Matteo Della Porta on the phase 3 COMMANDS trial examining luspatercept versus epoetin alfa in patients with lower-risk myleodysplastic syndrome | 22 Aug 2024 | 00:08:08 | |
Professor Matteo Giovanni Della Porta joins us to discuss the primary analysis of the phase 3 COMMANDS trial comparing luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndrome patients. Continue this conversation on social! | |||
| Enrico Lopriore on haemolytic disease of the fetus and newborn | 29 Nov 2023 | 00:12:33 | |
Professor Enrico Lopriore joins us to discuss a trial testing darbepoetin alfa to prevent postnatal anaemia in infants with haemolytic disease of the fetus and newborn. Continue this conversation on social! | |||
| Meletios Dimopoulos on relapsed and refractory multiple myeloma | 03 Oct 2023 | 00:11:00 | |
Professor Meletios Dimopoulos joins us to discuss two trials for patients with relapsed and refractory multiple myeloma - the first report of the DREAMM-3 phase 3 and long-term follow-up of the APOLLO phase 3 trial. Continue this conversation on social! | |||
| Eric Ohuma on haemoglobin concentrations and neonatal outcomes | 29 Aug 2023 | 00:16:27 | |
Dr Eric Ohuma joins us to tell us about a study recently published in The Lancet Haematology on the association between maternal haemoglobin concentrations and maternal and neonatal outcomes. Continue this conversation on social! | |||
| Margaret Ragni on tranexamic acid to treat heavy menstrual bleeding | 31 Jul 2023 | 00:13:13 | |
Professor Margaret Ragni joins us to discuss the VWDMin study, published in The Lancet Haematology. In this phase 3, randomised, crossover trial, recombinant von Willebrand factor and tranexamic acid are used to treat heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA. Continue this conversation on social! | |||
| Oreofe Odejide and Thomas Kuczmarski on mental health and lymphoma | 03 Jul 2023 | 00:16:32 | |
Dr Odejide and Dr Kuczmarski tell us about a study recently published in The Lancet Haematology on the effect of pre-existing mental health conditions on survival in patients with diffuse large B-cell lymphoma. Continue this conversation on social! | |||
| Alok Srivastava on fitusiran for patients with haemophilia A and B | 29 Mar 2023 | 00:18:41 | |
Professor Alok Srivastava tells us about two clinical trials being published in The Lancet and The Lancet Haematology on a new siRNA therapy called fitusiran for patients with haemophilia A and B. Continue this conversation on social! | |||
| Emmanuela E Ambrose on stroke prevention in children with sickle cell disease | 02 Mar 2023 | 00:11:31 | |
Dr Emmanuela E Ambrose tells us about the SPHERE trial on hydroxyurea dose escalation for primary stroke prevention in children with sickle cell disease in Tanzania Continue this conversation on social! | |||
| Sumit Gupta on racial and ethnic disparities in leukaemia survival outcomes | 30 Jan 2023 | 00:22:10 | |
Dr Sumit Gupta discusses how racial and ethnic disparities affect survival outcomes of children and young adults with acute lymphocytic leukaemia. Continue this conversation on social! | |||
| Xiao-Jun Huang on cellular therapy in China | 28 Nov 2022 | 00:28:10 | |
Professor Xiao-Jun Huang discusses this Lancet Haematology series on Cellular Therapy in China, covering the history, current research challenges, and future of HSCT and CAR T-cell therapies in China. Continue this conversation on social! | |||
| Glenn Pierce on haemophilia care in LMICs | 30 Aug 2022 | 00:34:55 | |
Dr Glenn Pierce discusses the World Federation of Hemophilia’s Humanitarian Aid Program which provides access to haemophilia care in low-income and lower-middle-income countries. Continue this conversation on social! | |||
| Kim Linton on follicular lymphoma | 07 Aug 2024 | 00:09:48 | |
Dr Kim Linton joins us to discuss the EPCORE NHL-1 trial testing monotherapy with the bispecific antibody epcoritamab for patients with relapsed or refractory follicular lymphoma. Continue this conversation on social! | |||
| Amy DeZern on the link between myelodysplastic syndrome and autoimmune disorders | 30 Jun 2022 | 00:12:50 | |
Dr Amy DeZern discusses the link between myelodysplastic syndrome and autoimmune disorders and the need for a multidisciplinary approach for the treatment of patients who have both. Continue this conversation on social! | |||
| Nicholas Crombie and Gavin Perkins on resuscitation with blood products compared with saline | 07 Mar 2022 | 00:15:05 | |
Dr Nicholas Crombie and Professor Gavin Perkins discuss their randomised phase 3 trial in which they investigated resuscitation with blood products compared with saline in patients with trauma-related haemorrhagic shock receiving prehospital care. Continue this conversation on social! | |||
| Fredrik Schjesvold on OCEAN phase 3 | 31 Jan 2022 | 00:12:24 | |
Dr Fredrik Schjesvold discusses the results of the OCEAN phase 3 trial testing melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide. Continue this conversation on social! | |||
| Jacob D Soumerai and Andrew D Zelenetz on the BOVen regimen for previously untreated patients with chronic lymphocytic leukaemia | 25 Nov 2021 | 00:11:59 | |
Dr Jacob D Soumerai and Prof Andrew D Zelenetz discuss their phase 2 trial of the BOVen regimen and MRD-driven treatment discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma. Continue this conversation on social! | |||
| Raul Cordoba on haematological malignancies in older people | 03 Nov 2021 | 00:16:24 | |
Dr Raul Cordoba discusses the joint Series between The Lancet Healthy Longevity and The Lancet Haematology on haematological malignancies in older people. Continue this conversation on social! | |||
| Obiageli Nnodu and Dennis Chao on child mortality from sickle cell disease in Nigeria | 21 Sep 2021 | 00:09:03 | |
Professor Obiageli Nnodu and Dr Dennis Chao join acting Deputy Editor Emma Cookson to talk about their new study describing modelling of child mortality as a result of sickle cell disease in Nigeria. Continue this conversation on social! | |||
| Zuguo Mei and Gary Brittenham on iron deficiency | 27 Jul 2021 | 00:08:34 | |
Senior Assistant Editor Ben Burwood speaks with Dr Zuguo Mei (Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA) and Dr Gary M Brittenham (Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY, USA) about their work defining physiologically based serum ferritin thresholds for iron deficiency. Continue this conversation on social! | |||
| Eugenia Trigoso Arjona (in English) on nursing and haematological care | 11 May 2021 | 00:28:34 | |
To mark International Nurses Day, Eugenia Trigoso Arjona, nurse coordinator at Hospital La Fe (Valencia, Spain) and chair of the European Society for Blood and Marrow Transplantation Nurses Global Education Committee, joins acting Editor-in-Chief Yaiza del Pozo Martin to discuss how nurses can reshape the future of haematological care. Continue this conversation on social! | |||
| Eugenia Trigoso Arjona (in Spanish) on nursing and haematological care | 11 May 2021 | 00:29:11 | |
Para el Día International de la Enfermera, Eugenia Trigoso Arjona, enfermera coordinadora en el Hospital La Fe (Valencia, España) y presidenta del comité de educación de la European Society for Blood and Marrow Transplantation Nurses hablo con la Editora Yaiza del Pozo Martin sobre como las enfermeras pueden remodelar el futuro de la hematología. Continue this conversation on social! | |||
| Nada Hamad on inclusion and diversity in haematology | 23 Feb 2021 | 00:30:02 | |
A/Prof Nada Hamad (St Vincent’s hospital, Sydney, Australia) joins Editor-in-Chief Dr Lan-Lan Smith to discuss inclusion and diversity in haematology-oncology and transplantation.
Continue this conversation on social! | |||
| Judy Truong on ferritin reference levels and iron deficiency | 05 Aug 2024 | 00:11:17 | |
Dr Judy Truong join us to discuss ferritin reference intervals and how adoption of evidence-based ferritin clinical decision limits can help clinicians detect and treat iron deficiency, minimising propagation of related health inequity and social injustice in medicine. Continue this conversation on social! | |||
| Dr Judith Boer on lymphoblastic leukaemia in children | 22 Dec 2020 | 00:10:24 | |
Editor-in-Chief, Dr Lan-Lan Smith, speaks with Dr Judith Boer (Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands) about outcome of ABL-class acute lymphoblastic leukaemia in children in the pre-tyrosine kinase inhibitor era. Continue this conversation on social! | |||
| Imatinib for paediatric leukaemia | 15 Dec 2018 | 00:08:33 | |
Andrea Biondi joins The Lancet Haematology to discuss his work on imatinib as a treatment for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia. Continue this conversation on social! | |||
| Predicting the risk of adenoviraemia | 31 Aug 2018 | 00:04:51 | |
Prashant Hiwarkar joins The Lancet Haematology to discuss his new paper, an investigation into whether serial faecal PCR monitoring can predict the risk of adenoviraemia and survival outcomes after HSCT. Continue this conversation on social! | |||
| Adverse events in haematological malignancies | 12 Jun 2018 | 00:12:31 | |
Lead author Gita Thanarajasingam joins The Lancet Haematology to discuss the new Commission on assessment and adverse event reporting in haematological malignancies. Continue this conversation on social! | |||
| EPO blood doping and cycling: The Lancet Haematology: June 29, 2017 | 30 Jun 2017 | 00:08:34 | |
Jules Heuberger talks about his study on the effectiveness of EPO use by cyclists. Continue this conversation on social! | |||
| Trauma-induced coagulopathy: The Lancet Haematology: June issue | 03 Jun 2017 | 00:09:10 | |
Petra Innerhofer discusses reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma. Continue this conversation on social! | |||
| Childhood leukaemia survival (CONCORD-2): The Lancet Haematology: April 11, 2017 | 12 Apr 2017 | 00:05:46 | |
Audrey Bonaventure discusses her CONCORD-2 study, monitoring survival trends of two types of childhood leukaemia in 53 countries between 1995 and 2009. Continue this conversation on social! | |||
| Superficial-vein thrombosis: The Lancet Haematology: February 15 2017 | 16 Feb 2017 | 00:10:27 | |
Jan Beyer discusses the SURPRISE trial of patients developing complications from superficial-vein thrombosis. Continue this conversation on social! | |||
| Economic burden of blood disorders in Europe: The Lancet Haematology: July 21, 2016 | 21 Jul 2016 | 00:09:32 | |
Dr Jose Leal discusses a study of the costs related to malignant and non-malignant blood disorders in Europe in 2012. Continue this conversation on social! | |||
| Castleman disease: The Lancet Haematology: March 17, 2016 | 18 Mar 2016 | 00:17:14 | |
David Fajgenbaum discusses a literature review to raise awareness of idiopathic multicentric Castleman disease, a poorly understood haematological disorder. Continue this conversation on social! | |||
| Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML | 16 Jul 2024 | 00:14:11 | |
Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia. Continue this conversation on social! | |||
| Deep-vein thrombosis: The Lancet Haematology, October 29, 2015 | 30 Oct 2015 | 00:08:23 | |
Walter Ageno discusses the use of an algorithm combining limited and whole-leg compression ultrasonography to diagnose deep-vein thrombosis. Continue this conversation on social! | |||
| Financial toxicity: The Lancet Haematology: September 17, 2015 | 17 Sep 2015 | 00:06:06 | |
Scott Huntington discusses the financial toxicity of oncology treatments Continue this conversation on social! | |||
| Idiopathic thrombocytopenic purpura: The Lancet Haematology: July 29, 2015 | 29 Jul 2015 | 00:06:24 | |
James Bussel discusses a study looking at treatment options for children facing idiopathic thrombocytopenic purpura. Continue this conversation on social! | |||
| INWORKS: The Lancet Haematology: June 29, 2015 | 29 Jun 2015 | 00:06:36 | |
Klervi Leuraud discusses a study reporting on the risk of developing leukaemia and lymphoma in workers monitored for radiation exposure. Continue this conversation on social! | |||
| Warfarin: The Lancet Haematology: May 26, 2015 | 26 May 2015 | 00:12:05 | |
Páll Önundarson describes a new method for monitoring clotting in patients treated with warfarin, which they tested in a non-inferiority, randomised clinical trial. Continue this conversation on social! | |||
| Atrial fibrillation and NOACs: The Lancet Haematology: April 2, 2015 | 02 Apr 2015 | 00:09:12 | |
Mahmoud Zureik discusses risk of bleeding in patients with non-valvular atrial fibrillation who switched and those who remained on a vitamin K antagonist. Continue this conversation on social! | |||
| 1 million stem cells: The Lancet Haematology: February 27, 2015 | 27 Feb 2015 | 00:13:20 | |
Dietger Niederwieser and Richard Lane discuss the journey to 1 million haematopoietic stem cell transplantations. Continue this conversation on social! | |||
| The Lancet Haematology: January 7, 2015 | 07 Jan 2015 | 00:10:14 | |
Guillermo Garcia-Manero discusses a phase 1/2 study on sequential azacitidine and lenalidomide in high-risk MDS and AML. Continue this conversation on social! | |||
| The Lancet Haematology: December 1, 2014 | 02 Dec 2014 | 00:11:02 | |
Gregory Kato discusses a phase I study for the treatment of leg ulcers for people with sickle-cell disease. Continue this conversation on social! | |||
| Banu Aygun on sickle cell anaemia | 23 May 2024 | 00:11:13 | |
Professor Banu Aygun joins us to discuss the REACH trial testing hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa. Continue this conversation on social! | |||
| Sabine Braat and Katherine Fielding on haemoglobin thresholds to define anaemia | 01 Mar 2024 | 00:18:06 | |
Dr Sabine Braat and Dr Katherine Fielding join us to discuss their study presenting new haemoglobin thresholds for defining anaemia. Continue this conversation on social! | |||
| Elisabeth Schorb on the MARTA phase 2 trial | 29 Feb 2024 | 00:09:23 | |
Doctor Elisabeth Schorb joins us to discuss the MARTA phase 2 trial, treating older, fit patients with primary diffuse large B-cell CNS lymphoma with high-dose chemotherapy and autologous stem-cell transplantation. Continue this conversation on social! | |||
| Stephan Ehl on paediatric autoimmune lymphoproliferative immunodeficiencies | 31 Jan 2024 | 00:13:03 | |
Professor Stephan Ehl joins us to discuss a prospective observational study on paediatric autoimmune lymphoproliferative immunodeficiencies. Continue this conversation on social! | |||
| Dr Sarah O'Brien on the PREVAPIX-ALL trial | 20 Dec 2023 | 00:13:50 | |
Dr Sarah O'Brien joins Lan-Lan Smith to discuss results of the phase 3 PREVAPIX-ALL trial, which compares direct oral anticoagulant apixaban to low-molecular-weight-heparin for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma. Continue this conversation on social! | |||
| Paolo Strati on off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lymphoma | 01 Jul 2025 | 00:21:49 | |
Associate Professor Paolo Strati (Department of Lymphoma and Myeloma, and Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA) joins us to discuss the results of a multicentre, open-label, phase 1 clinical trial of off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lymphoma. Read the full article: Continue this conversation on social! | |||